Can one injury really cause arthritis?

A single significant knee injury — a torn ligament, a fractured joint surface, or a badly damaged meniscus — can genuinely set in motion a process that ends in osteoarthritis. This is not the same condition as the gradual, age-related joint wear most people picture when they hear the word "arthritis". Doctors classify it separately as post-traumatic osteoarthritis (PTOA), and its biology is distinct: the clock starts at the moment of impact, not at the point years later when pain becomes impossible to ignore.

The injuries most commonly implicated are ACL tears, meniscal damage, and intra-articular fractures — events that disrupt the joint's structure, load distribution, or internal environment in ways that cartilage struggles to recover from. What makes PTOA particularly important to understand is its timeline. Research following female footballers 12 years after ACL injury found high rates of radiographic OA, pain, and functional limitation (Lohmander et al., Arthritis Rheum. 2004), and population-level data place symptomatic knee OA at roughly 10–15 years after ACL reconstruction.

That gap is not a reason for passivity — it is a window during which the trajectory can often be managed.

The biological cascade inside the joint

Inside cartilage, the damage from a forceful impact happens far faster than pain or stiffness would suggest. The impact delivers a sudden, concentrated shock to chondrocytes — the cells responsible for maintaining cartilage — triggering an intense burst of reactive oxygen species (ROS) from their mitochondria. Think of it as a localised oxidative flash: the cells are overwhelmed rapidly, and many die outright. This is not a slow erosion; it is an acute, targeted injury at the cellular level.

The surviving chondrocytes face a different fate. Rather than recovering and resuming normal cartilage maintenance, many enter a state called senescence. Senescent chondrocytes permanently stop producing the extracellular matrix that keeps cartilage resilient and instead begin releasing pro-inflammatory signals into the joint. In effect, the joint's own repair cells become drivers of further breakdown — converting an acute injury into a chronically degenerative environment.

This sequence is mechanistically different from age-related OA, where degeneration tends to be gradual and spread across the joint surface. In PTOA, the damage originates from a defined event and propagates outward from there.

Where the injury involves an intra-articular fracture requiring surgical fixation, there is an additional consideration: the repair procedure itself may provoke a second biological response on top of the original trauma. This does not mean surgery should be avoided when it is necessary, but it underlines why specialist follow-up after fixation matters — preclinical models show measurable cartilage degeneration developing as early as 12 weeks post-injury, even in joints reduced anatomically.

The decade-long window between injury and diagnosis

Radiographic changes and lived symptoms do not always arrive together. A scan taken during a routine review might show early joint space narrowing and subchondral changes consistent with OA — yet the patient feels only occasional stiffness after sport, nothing they would call a problem. That gap between what imaging shows and what a person experiences is clinically meaningful: a structural finding on its own is not a diagnosis, and many people in the latent phase attribute mild aching or reduced range of movement to the original injury rather than recognising the beginning of a degenerative process.

What closes that gap faster is concomitant meniscal damage. Research from the Framingham cohort established that meniscal lesions are an independent contributor to OA progression — not a bystander injury that heals and steps aside. Meniscectomy alters how load is distributed across the joint surface, and that changed mechanical environment accelerates the cartilage breakdown described in the previous section. The practical implication is straightforward: patients who sustained both ligament and meniscal damage at the time of the original event are likely to move through the latent window more quickly than those with an isolated ACL tear.

It is worth noting that ACL reconstruction addresses joint instability — the surgery itself does not cause OA; the injury does. Staying aware of symptom changes in the years after any significant knee trauma, rather than assuming all is resolved once the acute phase has passed, gives clinicians the best opportunity to intervene before structural loss becomes extensive.

Why cartilage cannot repair itself

Unlike bone, muscle, or skin, cartilage has no direct blood supply. When those tissues are damaged, the vascular network delivers the cellular machinery for repair — clotting factors, growth signals, stem cells carried in blood. Cartilage cannot call on any of that. What the joint has at the time of injury is, in essence, what it is left with.

In practice, small cartilage defects may stabilise through mechanical adaptation, but injuries exceeding roughly 1 cm² in diameter are unlikely to self-repair and tend to worsen progressively over time. The threshold is not a sharp cut-off, but it marks the point at which the tissue's limited intrinsic capacity is clearly exceeded.

In post-traumatic cases this biological ceiling has additional weight. The acute cell death that follows a high-impact event means the joint is already working from a reduced base — even in the early weeks after injury, there are fewer viable chondrocytes than in an uninjured knee. Each subsequent increment of loss occurs in a joint that was already compromised from the outset.

The practical implication is about timing: injection and biological therapies operate in a structural environment that still has cartilage to support and protect. Once full-thickness loss is established, that environment changes considerably. 'Wait and see' has a natural time-limit.

The injection pathway — from first-line options to advanced biologics

For most patients, the pathway begins well before injections enter the picture. Physiotherapy to rebuild strength and neuromuscular control, load modification, and anti-inflammatory medication where tolerated are the appropriate first response to post-traumatic knee symptoms — and this stage should generally be worked through before intra-articular treatment is considered.

Hyaluronic acid

When conservative measures have not produced adequate relief, hyaluronic acid (HA) viscosupplementation is typically the first injection step. HA is a naturally occurring component of synovial fluid; intra-articular injection aims to restore lubrication and cushioning as the joint's own fluid degrades through the OA process. Cochrane-level evidence (Bellamy et al., 2006) supports its use in knee OA, with the most consistent benefit seen in early-to-moderate disease. Systematic reviews indicate that efficacy diminishes at end-stage OA — which is why patients presenting earlier in the post-traumatic window tend to be stronger candidates. Single-injection HA formulations have further lowered the access and convenience threshold for eligible patients compared with multi-dose courses.

Platelet-rich plasma

PRP concentrates growth factors and anti-inflammatory proteins from the patient's own blood for direct intra-articular delivery. Its evidence base is younger than HA's: PRP reached widespread clinical use more recently, and the published literature (Filardo, Kon et al.) reflects considerable variation in preparation protocols and patient-selection criteria between trials, which makes definitive comparative conclusions difficult. The biological rationale is well established and clinical interest continues to grow; how PRP's effect size compares directly with HA in head-to-head terms remains an active research question rather than a settled one.

Arthrosamid®

Arthrosamid® (2.5% polyacrylamide hydrogel) works differently from both HA and PRP. Being non-biodegradable, it is not absorbed after injection and remains in the joint long term as a mechanical cushion. A 12-month open-label follow-up study (Bliddal et al., J Orthop Surg Res, 2024) reported a favourable safety and efficacy profile. It is typically considered when earlier injection options have not delivered sufficient relief, and its permanence places it in a distinct category within the intra-articular pathway rather than as a straightforward next increment on the HA step.

When to see a specialist

Three signals, appearing together, suggest the time for GP-level management has passed: persistent or worsening knee pain following a significant prior injury; failure to gain adequate relief from a structured course of physiotherapy and anti-inflammatory medication; and the arrival of mechanical symptoms — locking, catching, or sudden giving way — in a joint that has already been injured. Any one of these alone may not be sufficient reason to escalate; the combination is a clearer prompt.

Imaging findings on their own are not an escalation trigger. An MRI or X-ray that shows cartilage thinning, a meniscal signal change, or early joint-space narrowing represents one input into clinical assessment — it is not a verdict in isolation. Many people have structural changes on imaging that generate no symptoms at all, and a structural finding only becomes clinically significant when it correlates with what the patient is actually experiencing. A specialist's role is to make that correlation.

A specialist MSK assessment is less daunting in practice than the phrase suggests. It typically covers the history of the original injury and any subsequent events, the current symptom pattern (location, timing, what aggravates and what eases it), a hands-on clinical examination of the joint, and review of any imaging already taken. The aim is to establish where on the post-traumatic pathway the joint is, and what the realistic options are at that stage.

Attending an assessment does not commit a patient to any particular treatment. Surgical options — cartilage repair procedures, joint replacement — sit further along the pathway and require their own separate evaluation. An assessment focused on the injection pathway is exactly that: a staged, reversible conversation about what conservative and biologic options remain available before more definitive intervention becomes relevant.

1. [1] Post-traumatic arthritis — Wikipedia. https://en.wikipedia.org/?curid=56957582 https://en.wikipedia.org/?curid=56957582